Cargando…
Lung Function After Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer, Changes and Predictive Markers
INTRODUCTION: The present study explores changes in pulmonary function, symptoms and radiological signs of pneumonitis after curatively intended stereotactic body radiation therapy (SBRT). METHODS: All inoperable, early-stage non-small cell lung cancer patients treated with stereotactic body radiati...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8181743/ https://www.ncbi.nlm.nih.gov/pubmed/34109123 http://dx.doi.org/10.3389/fonc.2021.674731 |
_version_ | 1783704119273324544 |
---|---|
author | Berg, Janna Ramberg, Christina Haugstvedt, Jon Olav Sulheim Bengtson, May-Bente Gabrielsen, Anne-Marie Brustugun, Odd Terje Halvorsen, Ann Rita Helland, Åslaug |
author_facet | Berg, Janna Ramberg, Christina Haugstvedt, Jon Olav Sulheim Bengtson, May-Bente Gabrielsen, Anne-Marie Brustugun, Odd Terje Halvorsen, Ann Rita Helland, Åslaug |
author_sort | Berg, Janna |
collection | PubMed |
description | INTRODUCTION: The present study explores changes in pulmonary function, symptoms and radiological signs of pneumonitis after curatively intended stereotactic body radiation therapy (SBRT). METHODS: All inoperable, early-stage non-small cell lung cancer patients treated with stereotactic body radiation therapy (SBRT) from 2014-2017 were included in this single-centre study. They were followed regularly for 12 months after treatment. The patients were classified into three groups based on radiology and symptomatology: no radiation pneumonitis, asymptomatic and symptomatic radiation pneumonitis. RESULTS: Forty-four patients with stage IA-IIB disease were treated with 45–56 Gy in 3–8 fractions. The median age was 75 years, 43% of the patients were female; 60% of the patients had a COPD in GOLD grade of 2-4, and 95.5% were active or former smokers. Symptomatic radiation pneumonitis occurred in 18% of the patients and asymptomatic pneumonitis as defined by radiology, in 39%. The mean of forced expiratory volume in 1 second (FEV1) and diffusion capacity for carbon monoxide (DLCO) decreases for all patients during the first years were higher than one would expect from physiologic ageing. FEV1 and DLCO in percent decrease 7-8% at 1-1.5 months in the symptomatic radiation pneumonitis group. CT scan findings consistent with radiation pneumonitis occurred after a median of 2.9 months in the symptomatic and 5.4 months in the asymptomatic radiation pneumonitis groups. In the group with symptomatic radiation pneumonitis, symptoms, as measured by the Clinical COPD questionnaire score, significantly increased at 3 and 6 months. Significant higher maximum doses to the critical lung volumes DC1000cm(3) (1000 cm(3) of lung receiving a given dose or less) and DC 1500cm(3) (1500 cm(3) of lung receiving a given dose or less) were observed in patients who developed radiation pneumonitis. CONCLUSION: Early decrease in measured FEV1 and DLCO occurred before imaging changes and symptoms and might indicate the development of symptomatic radiation pneumonitis. The dose to critical lung volumes of DC1000 cm(3) and DC1500 cm(3) may predict the risk for the development of symptomatic radiation pneumonitis. |
format | Online Article Text |
id | pubmed-8181743 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-81817432021-06-08 Lung Function After Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer, Changes and Predictive Markers Berg, Janna Ramberg, Christina Haugstvedt, Jon Olav Sulheim Bengtson, May-Bente Gabrielsen, Anne-Marie Brustugun, Odd Terje Halvorsen, Ann Rita Helland, Åslaug Front Oncol Oncology INTRODUCTION: The present study explores changes in pulmonary function, symptoms and radiological signs of pneumonitis after curatively intended stereotactic body radiation therapy (SBRT). METHODS: All inoperable, early-stage non-small cell lung cancer patients treated with stereotactic body radiation therapy (SBRT) from 2014-2017 were included in this single-centre study. They were followed regularly for 12 months after treatment. The patients were classified into three groups based on radiology and symptomatology: no radiation pneumonitis, asymptomatic and symptomatic radiation pneumonitis. RESULTS: Forty-four patients with stage IA-IIB disease were treated with 45–56 Gy in 3–8 fractions. The median age was 75 years, 43% of the patients were female; 60% of the patients had a COPD in GOLD grade of 2-4, and 95.5% were active or former smokers. Symptomatic radiation pneumonitis occurred in 18% of the patients and asymptomatic pneumonitis as defined by radiology, in 39%. The mean of forced expiratory volume in 1 second (FEV1) and diffusion capacity for carbon monoxide (DLCO) decreases for all patients during the first years were higher than one would expect from physiologic ageing. FEV1 and DLCO in percent decrease 7-8% at 1-1.5 months in the symptomatic radiation pneumonitis group. CT scan findings consistent with radiation pneumonitis occurred after a median of 2.9 months in the symptomatic and 5.4 months in the asymptomatic radiation pneumonitis groups. In the group with symptomatic radiation pneumonitis, symptoms, as measured by the Clinical COPD questionnaire score, significantly increased at 3 and 6 months. Significant higher maximum doses to the critical lung volumes DC1000cm(3) (1000 cm(3) of lung receiving a given dose or less) and DC 1500cm(3) (1500 cm(3) of lung receiving a given dose or less) were observed in patients who developed radiation pneumonitis. CONCLUSION: Early decrease in measured FEV1 and DLCO occurred before imaging changes and symptoms and might indicate the development of symptomatic radiation pneumonitis. The dose to critical lung volumes of DC1000 cm(3) and DC1500 cm(3) may predict the risk for the development of symptomatic radiation pneumonitis. Frontiers Media S.A. 2021-05-24 /pmc/articles/PMC8181743/ /pubmed/34109123 http://dx.doi.org/10.3389/fonc.2021.674731 Text en Copyright © 2021 Berg, Ramberg, Haugstvedt, Bengtson, Gabrielsen, Brustugun, Halvorsen and Helland https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Berg, Janna Ramberg, Christina Haugstvedt, Jon Olav Sulheim Bengtson, May-Bente Gabrielsen, Anne-Marie Brustugun, Odd Terje Halvorsen, Ann Rita Helland, Åslaug Lung Function After Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer, Changes and Predictive Markers |
title | Lung Function After Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer, Changes and Predictive Markers |
title_full | Lung Function After Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer, Changes and Predictive Markers |
title_fullStr | Lung Function After Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer, Changes and Predictive Markers |
title_full_unstemmed | Lung Function After Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer, Changes and Predictive Markers |
title_short | Lung Function After Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer, Changes and Predictive Markers |
title_sort | lung function after stereotactic body radiation therapy for early-stage non-small cell lung cancer, changes and predictive markers |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8181743/ https://www.ncbi.nlm.nih.gov/pubmed/34109123 http://dx.doi.org/10.3389/fonc.2021.674731 |
work_keys_str_mv | AT bergjanna lungfunctionafterstereotacticbodyradiationtherapyforearlystagenonsmallcelllungcancerchangesandpredictivemarkers AT rambergchristina lungfunctionafterstereotacticbodyradiationtherapyforearlystagenonsmallcelllungcancerchangesandpredictivemarkers AT haugstvedtjonolavsulheim lungfunctionafterstereotacticbodyradiationtherapyforearlystagenonsmallcelllungcancerchangesandpredictivemarkers AT bengtsonmaybente lungfunctionafterstereotacticbodyradiationtherapyforearlystagenonsmallcelllungcancerchangesandpredictivemarkers AT gabrielsenannemarie lungfunctionafterstereotacticbodyradiationtherapyforearlystagenonsmallcelllungcancerchangesandpredictivemarkers AT brustugunoddterje lungfunctionafterstereotacticbodyradiationtherapyforearlystagenonsmallcelllungcancerchangesandpredictivemarkers AT halvorsenannrita lungfunctionafterstereotacticbodyradiationtherapyforearlystagenonsmallcelllungcancerchangesandpredictivemarkers AT hellandaslaug lungfunctionafterstereotacticbodyradiationtherapyforearlystagenonsmallcelllungcancerchangesandpredictivemarkers |